← Back to headlines
AbbVie Reports Positive Late-Stage Results for Subcutaneous Skyrizi in Crohn's Disease
AbbVie announced positive late-stage clinical trial results for its subcutaneous Skyrizi treatment in patients with Crohn's disease, indicating potential for a new therapeutic option.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
